Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Colorectal Neoplasms 112Breast Neoplasms 87Carcinoma, Non-Small-Cell Lung 85Glioblastoma 72Ovarian Neoplasms 62Brain Neoplasms 45Lung Neoplasms 41Glioma 41Fallopian Tube Neoplasms 41Neoplasms 38Colonic Neoplasms 34Gliosarcoma 33Carcinoma, Renal Cell 32Rectal Neoplasms 31Neoplasm Metastasis 29Pancreatic Neoplasms 19Carcinoma, Hepatocellular 19Melanoma 18Adenocarcinoma of Lung 18Astrocytoma 15Kidney Neoplasms 13Stomach Neoplasms 12Prostatic Neoplasms 12Uterine Cervical Neoplasms 11Oligodendroglioma 11Liver Neoplasms 11Esophageal Neoplasms 11Sarcoma 10Adenocarcinoma, Bronchiolo-Alveolar 10Central Nervous System Neoplasms 9

Interventions

Paclitaxel 6Carboplatin 6Gemcitabine 3pembrolizumab 2Irinotecan 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2sintilimab 1pertuzumab 1pemigatinib 1olaparib 1ivosidenib 1ipatasertib 1etoposide phosphate 1erythromycin propionate-N-acetylcysteinate 1entrectinib 1cobimetinib 1belinostat 1atezolizumab 1antineoplaston AS 2-1 1antineoplaston A10 1alectinib 1Vemurafenib 1Surveys and Questionnaires 1Oxaliplatin 1HhAntag691 1Everolimus 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms, Unknown Primary × Bevacizumab × Clear all
NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00360360 2013-12-04

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
60 enrolled 6 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡